JOURNAL OF CLINICAL ONCOLOGY, cilt.21, sa.14, ss.2636-2644, 2003 (SCI-Expanded)
Purpose : Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone.